Achieve Life Sciences, INC

Achieve Life Sciences Inc. announced amendments to its charter to increase authorized shares and reported election results for its board of directors and ratification of its auditor.

Achieve Life Sciences, Inc. announced the appointment of two new directors to its Board, effective May 29, 2026.

Achieve Life Sciences announced a significant private placement of up to $354 million, appointed a new CEO, and provided updates on its cytisinicline development and manufacturing readiness.

Achieve Life Sciences has entered into a $354 million private placement agreement to fund cytisinicline development and commercialization while announcing a CEO transition.

Achieve Life Sciences announced its fourth quarter and full year 2025 financial results, alongside significant progress in cytisinicline's regulatory pathway and commercial readiness, including a new U.S. manufacturing partnership.

Achieve Life Sciences announced its third quarter 2025 financial results and provided updates on its cytisinicline program, including an FDA PDUFA date and a National Priority Voucher for vaping cessation.

Achieve Life Sciences reported its first quarter 2026 financial results, highlighting a net loss of $10.2 million and a significant capital raise of $180 million, while also anticipating a delay in FDA approval for cytisinicline.

Achieve Life Sciences reports Q3 2025 results, highlighting FDA acceptance of its cytisinicline NDA for smoking cessation and a national priority voucher for vaping cessation, amidst ongoing financing needs and a supplier dispute.

Achieve Life Sciences submitted its New Drug Application for cytisinicline for smoking cessation and secured significant funding, extending its cash runway into late 2026.

Achieve Life Sciences reports a net loss of $12.8 million for Q1 2025 while advancing cytisinicline towards NDA submission and Phase 3 vaping cessation trials.

Achieve Life Sciences' Q3 2024 report details financial results and progress in clinical trials for cytisinicline, including the completion of enrollment for the ORCA-OL safety trial.

Achieve Life Sciences reports a net loss of $15.0 million for the first half of 2024, while advancing its cytisinicline program towards potential FDA approval.

Achieve Life Sciences amends its 2025 Annual Report to include updated corporate governance, executive compensation, and director information.

Achieve Life Sciences' 2025 annual report highlights significant operating losses, ongoing financing needs, and potential FDA approval delays for cytisinicline, despite positive clinical trial results and breakthrough therapy designation.

Achieve Life Sciences provides an update on its clinical development program for cytisinicline and reports its financial results for the year ended December 31, 2024.

Achieve Life Sciences' 10-K filing details the company's financial status, clinical trial progress, and regulatory pathway for its lead product candidate, cytisinicline.

Thomas Sellig, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Christopher Nathan Martin, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Aaron Royston, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Reid Alexander Waldman, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Richard Alistair Stewart, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Jeffrey S Farrow, a Director of Achieve Life Sciences, Inc., reported multiple transactions in common stock on July 27, 2026.

Achieve Life Sciences announces its 2026 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation approval, and a significant increase in authorized shares.

Achieve Life Sciences is holding its annual stockholder meeting on June 4, 2025, to elect directors, ratify the appointment of its accounting firm, and approve an amendment to its equity incentive plan.

Achieve Life Sciences will hold its annual stockholders meeting virtually on June 5, 2024, to elect directors and ratify the appointment of its independent accounting firm.

venBio Global Strategic Fund V, L.P. and its general partner have acquired a 9.99% beneficial ownership stake in Achieve Life Sciences, Inc. through a private placement, securing a board seat.

TPG Auriga has acquired a 12.6% beneficial ownership stake in Achieve Life Sciences through a private placement transaction.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have reported beneficial ownership of 8.3% of Achieve Life Sciences, Inc. common stock, primarily through managed accounts.

Vivo Opportunity Funds collectively report beneficial ownership of 5.3 million shares, representing 5.0% of Achieve Life Sciences' outstanding common stock, including shares issuable upon warrant exercise.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have disclosed a beneficial ownership of 6,369,252 shares, representing 6.2% of the outstanding common stock of Achieve Life Sciences, Inc.

Paradigm BioCapital Advisors and Dr. Senai Asefaw have reported a 9.2% beneficial ownership stake in Achieve Life Sciences, Inc. following recent equity issuance.

Venrock Healthcare Capital Partners and affiliates have reported a 5.2% beneficial ownership stake in Achieve Life Sciences, Inc. following a recent private placement.

Franklin Resources, Inc. and its affiliate Franklin Advisers, Inc. reported beneficial ownership of 11.5% of Achieve Life Sciences, Inc. common stock, including warrants.